Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis

Narita, Shintaro; Nara, Taketoshi; Kanda, Sohei; Numakura, Kazuyuki; Saito, Mitsuru; Inoue, Takamitsu; Satoh, Shigeru; Nanjo, Hiroshi; Tsuchiya, Norihiko; Mitsuzuka, Koji; Koie, Takuya; Kawamura, Sadafumi; Οhyama, Chikara; Tochigi, Tatsuo; Arai, Yoichi; Habuchi, Tomonori

doi:10.1016/j.clgc.2018.09.019

Cited by 17 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We summarized several lines of clinical evidence showing NCHT with docetaxel plus ADT before RP (Table 4) [6][7][8][9][10][11][12][13][14]. This study is the longest follow-up study ever published of NCHT (as shown in Table 4).…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Background: Radical prostatectomy (RP) is the standard treatment in patients with high-risk prostate cancer (PCa). However, there is a high rate of recurrence, and new approaches are required to improve surgical efficacy. Here, we evaluated the feasibility and safety of neoadjuvant chemohormonal therapy (NCHT) before RP for Japanese patients with high-risk localized prostate cancer (PCa). Methods: From February 2009 to April 2016, 21 high-risk patients were enrolled in this prospective study. Patients were treated with docetaxel (70 mg/m2) every four weeks for three cycles and luteinizing hormone-releasing hormone agonist. Patients with grade 3–4 toxicities had 25% dose reductions for the following course. Results: Median follow-up was 88.6 months. The dose of docetaxel was reduced in 13 patients. The estimated five-year biochemical progression-free survival (bPFS) rate was 57.1%. National Comprehensive Cancer Network criteria (high-risk, but not very high-risk (nVHR) versus VHR) was associated with bPFS (p = 0.03). Five-year bPFS rates in the nVHR and VHR groups were 76.9% and 25.0%, respectively. There was a significant difference in bPFS between the nVHR and VHR groups (p = 0.023) by Kaplan–Meier analysis. Conclusions: Although our study included a small number of cases, at least in our exploration, NCHT was safe and feasible. However, more extensive treatment modalities are needed to improve outcomes, especially in VHR patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Docetaxel at a dose of 30 mg/m 2 was administered intravenously, with 560 mg of estramustine phosphate orally for 6 consecutive weeks. The clinical outcomes of the study have been reported in previous literature [7,8].…”

Section: Treatment Regimenmentioning

confidence: 96%

“…The patients were prospectively enrolled in the phase II study to assess the impact of CHT with ADT, docetaxel, and estramustine phosphate, followed by RP in patients with high-risk PCa between 2006 and 2016 at our institution [7,8]. Eligible patients had histopathologically confirmed localized, high-risk PCa and were candidates for RP at our hospital as reported previously [7,8]. The patients were excluded if they had received prior therapy for PCa, prior invasive malignancy, any serious comorbidity, or an Eastern Cooperative Oncology Group performance status of ≥2.…”

Section: Patientsmentioning

confidence: 99%

“…Supplementary Figure 1 shows the schedule of CHT at our institution [8]. Briefly, the CHT protocol involved combined androgen blockade with 11.25 mg leuprorelin or goserelin subcutaneously once every 3 months and 81 mg bicalutamide orally for the first 12 weeks.…”

Section: Treatment Regimenmentioning

confidence: 99%

“…However, whether the same extent of benefit is obtained if these therapies are applied at an earlier stage, such as high-risk localized PCa, remains controversial. We previously reported the outcomes of neoadjuvant chemohormonal therapy (CHT) combined with ADT, docetaxel, and estramustine phosphate, followed by radical prostatectomy (RP) [7,8] . In these studies, we found the limitation of the effect of CHT in patients with high-risk localized PCa, therefore indicating the importance of elucidating the molecular mechanisms underlying the resistance to docetaxel-CHT to overcome resistance and improve the outcome for the treatment of high-risk localized PCa.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Although docetaxel-based chemohormonal therapy (CHT) is one of the standard treatments for castration-resistant prostate cancer (CRPC), pertinent biomarkers and precise mechanisms involved in the resistance for CHT for CRPC remain unknown. We investigated the relationship between chemohormonal resistance and the expression of steroid receptors and Hippo pathway proteins using a docetaxel-resistant prostate cancer (PCa) cell line and human PCa tissues in patients who underwent surgery with and without neoadjuvant therapy. Methods: A docetaxel-resistant subline (22Rv1-DR) was generated to assess Hippo pathway protein expression and the effect of YAP1 inhibition on cellular characteristics. A tissue microarray with 203 cores from 70 high-risk localized PCa tissues was performed to assess steroid receptor and Hippo pathway protein expressions. Results: Nuclear YAP (nYAP) expression was higher in 22RV-1-DR than in parental 22Rv-1 and YAP1 knockdown suppressed cell proliferation of 22Rv1-DR. Steroid receptor and Hippo pathway protein expressions varied among three different neoadjuvant groups, and nYAP1 expression was the highest in the CHT group. The patients with high nYAP in residual cancer after neoadjuvant CHT had a significantly higher biochemical recurrence (BCR) rate than those with low nYAP1. On multivariate analysis, the high nYAP1 was an independent prognostic factor for BCR. Conclusions: nYAP expression is a potential biomarker in high-risk patients treated with docetaxel-based CHT. Steroid receptors and Hippo pathway proteins may play a role in the chemohormonal resistance in advanced PCa.

show abstract

Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients

et al. 2023

View full text Add to dashboard Cite

Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis

Cited by 17 publications

References 29 publications

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients

Contact Info

Product

Resources

About